OverviewSuggest Edit

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system diseases, pain and various types of cancer. The Company’s lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
TypePublic
Founded2006
HQNew York, US
Websiteanavex.com

Latest Updates

Employees (est.) (Sept 2019)16(+24%)
Share Price (Sept 2020)$4.1
Cybersecurity ratingBMore

Key People/Management at Anavex

Christopher U. Missling

Christopher U. Missling

CEO
Tom Skarpelos

Tom Skarpelos

Director
Tasos Zografidis

Tasos Zografidis

Vice President Clinical Operations
Ulrich Elben

Ulrich Elben

Vice President of Preclinical Operations
Show more

Anavex Office Locations

Anavex has offices in New York and Reno
New York, US (HQ)
51 W 52nd St
Reno, US
50 W. Liberty, 50 W Liberty St #880
Show all (2)

Anavex Financials and Metrics

Anavex Revenue

USD

Net income (Q3, 2020)

(6.5m)

Market capitalization (22-Sept-2020)

244.4m

Closing stock price (22-Sept-2020)

4.1

Cash (30-Jun-2020)

27.6m
Anavex's current market capitalization is $244.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Sales and marketing expense

133.8k

General and administrative expense

30.1k9.1k4.0k2.2m4.8m8.3m5.0m6.0m6.8m

R&D expense

2.6m2.7m263.8k732.4k2.3m7.3m10.7m13.3m22.3m

Operating expense total

2.8m2.7m267.9k3.0m7.1m15.6m15.7m19.3m29.1m
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Sales and marketing expense

38.7k15.0k7.6k

General and administrative expense

5.0k3.2k2.3k3.0k112.0295.02.3k903.0k733.8k452.1k451.2k713.5k3.9m852.8k1.4m1.1m1.1m1.4m1.5m1.6m1.8m2.1m1.4m1.4m1.7m1.4m

R&D expense

778.0k1.7m429.6k394.0k127.0k560.039.0k5.2k118.2k265.0k318.6k407.1k799.5k670.7k1.3m917.3k2.0m2.5m2.3m3.2m3.0m5.7m6.1m5.8m6.3m6.1m6.7m

Operating expense total

821.6k1.7m439.5k396.9k127.0k672.039.3k7.5k1.0m998.8k770.7k858.3k1.5m4.5m2.2m2.3m3.2m3.6m3.7m4.7m4.6m7.5m8.1m7.1m7.7m7.8m8.1m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

134.7k11.4k345.1k7.3m15.3m9.2m27.4m22.9m22.2m

Prepaid Expenses

9.6k48.4k89.1k100.8k335.9k1.3m501.0k

Current Assets

200.6k12.6k393.4k7.4m15.5m27.8m24.3m25.3m

PP&E

2.4k576.02.2k1.3k
USDQ3, 2011

Financial Leverage

-1.3 x
Show all financial metrics

Anavex Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Anavex Online and Social Media Presence

Embed Graph

Anavex News and Updates

Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences

Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference

Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome

NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease,…

Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

Anavex shares rise in advance of Alzheimer's meeting

Shares of Anavex Life Sciences Corp. edged up 1% in morning trading after the biopharmaceutical company said its experimental mid-stage treatment for Alzheimer's disease reported lower rates of cognitive decline. Interim data is expected to be presented at the Clinical Trials On Alzheimer's Disease…

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s diseas…
Show more

Anavex Blogs

Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)

Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)   NEW YORK – July 6, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of…

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial   NEW YORK – June 16, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differe…

Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease

Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease   NEW YORK – June 4, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-sta…

Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)

Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)   NEW YORK – May 21, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of …

Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates

 Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – May 7, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company deve…

Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020

Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020 Conference Call and Webcast To be Held Thursday, May 7 2020 4:30pm Eastern Time NEW YORK – May 5, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage bi…
Show more

Anavex Frequently Asked Questions

  • When was Anavex founded?

    Anavex was founded in 2006.

  • Who are Anavex key executives?

    Anavex's key executives are Christopher U. Missling, Tom Skarpelos and Tasos Zografidis.

  • How many employees does Anavex have?

    Anavex has 16 employees.

  • Who are Anavex competitors?

    Competitors of Anavex include Citryll, Shanghai Henlius Biotech and Celgene.

  • Where is Anavex headquarters?

    Anavex headquarters is located at 51 W 52nd St, New York.

  • Where are Anavex offices?

    Anavex has offices in New York and Reno.

  • How many offices does Anavex have?

    Anavex has 2 offices.